Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
john..QUOTE.. "in the right hands would mean massive lawsuits against infringing parties with new gsk/teva precedent.".....
I assume that that by "in the right hands" you mean in the hands of a BP, which is able to afford a law firm to prosecute the infringement case....Perhaps Amarin could now entice a patent law firm to take this case on a contingency basis.
Hikma and Reddy, in an ongoing conspiracy with insurance companies, have openly infringed on Amarin's CVD patents and have already stolen millions of dollars that rightfully belonged to Amarin.
The last two days have been good for Pfizer... with the news about their blockbuster drug for weight loss and the renewed interest in their Covid vaccine.
I assume the increase in the market cap of their stock during these two days would be more than enough to fund a BO of Amarin.
My guess...I assume that Teva did not buy all that IPE in order to market their own generic to compete on the same basis with the other four already approved gV products...plus with Amarin's branded Vascepa
In order to make use of their inventory, Teva will need a large market...They will acquire Amarin and proceed to sell branded Vascepa at low prices in the U.S., Europe, and ROW....Teva will pay lower prices for their API because of their increased volume of purchases.
Teva will advertise and emphasize the superiority of their product over gV.
EPA is the term being used by Doctors more and more while Vascepa is being used less and less...Amarin should now drop the name Vascepa and call the product what it is...EPA PURE...unless someone has already trademarked that name.
Louie...good to hear from you again...
I have felt it is still possible that, with the current backing of Amarin management, a new appeal could be made to SCOTUS concerning the fraud in the judge DU ninth circuit case, which appeal might lead to a reexamination of judge Du's erroneous decision to invalidate Amarin's high triglyceride patent...and SCOTUS might accept the case for trial.
The Amarin-Teva agreement dealt ONLY with Amarin's High Trig patent...NOT with Amarin's CVD patent....If Teva's gV is used for the CVD indication, it will be infringing once again, as it did with Teva's skinny label in the GSK case, which cost them $285 million in damages
P...If that was the condition of the settlement, why would Healthnet have insisted that the terms of the agreement be kept secret?
P...The reason Healthnet settled the lawsuit was because they feared that they would have to pay a huge monetary award to Amarin for their infringement on Amarin's CVD patent.
P...Thank you for that astute analysis...This indicates to me that Amarin MUST come up with a product, which is better than gV, in order to avoid a race to the bottom on price....Perhaps a FDC with a statin plus MND-2119 could be that better product, especially if the need for Amarin to pay royalties to Mochida is not too burdensome...Thus far, we have been given no clues about that aspect of their "collaboration" contract.
Teva also markets generic Lovaza in addition to gV...and probably sells more gL than gV...even though they must be aware that generic Lovaza is a useless waste of patients' money for reducing CVD, which is the main indication patients are buying it for...Now Teva has decided to switch away from marketing generic drugs to being a marketer of branded drugs.
Teva totally lacks credibility...and IMO is as bad as Hikma and Dr. Reddy, who prey upon the public with bad, but slightly cheaper products.
This Scotus decision seems to be in line with a pattern of court decisions by conservative, as well as liberal, judges, to weaken patent protections.
This Amgen decision seems to be the tip of the iceberg of what is becoming a pattern of invalidation of patents altogether...The current theory is that...if you really don't fully understand the science or the history behind a patent, just make it go away.
Patent lawyers have to be scientists and teachers in addition to being litigators.
Average ages in most countries are trending to be older...There are bound to be more patients ,needing care for acute and chronic diseases...As medical expenditures by governments become more restrictive, expensive medicines that extend lives for a few months or years, such as cancer therapies, will necessarily be made less available to patients by governments which pay the bills...and more available to patients with cardiovascular diseases, especially for less expensive medicines, which which extend lives for many more years.
Pfizer has chosen to pay $43 billion for Seagen's cancer drugs...rather than 4 billon for Amarin's Vascepa...This may not have been a good move at this point in time..even taking into account Pfizer's multiple upcoming patent expirations.
Average ages in most countries are trending to be older...There are bound to be more patients ,needing care for acute and chronic diseases...As medical expenditures by governments become more restrictive, expensive medicines that extend lives for a few months or years, such as cancer therapies, will necessarily be made less available to patients by governments which pay the bills...and more available to patients with cardiovascular diseases, especially for less expensive medicines, which which extend lives for many more years.
Pfizer has chosen to pay $43 billion for Seagen's cancer drugs...rather than 4 billon for Amarin's Vascepa...This may not have been a good move at this point in time..even taking into account Pfizer's multiple upcoming patent expirations.
I'll admit that I'm not very knowledgeable in the ways that activist investors make money for themselves and for shareholders...I do feel, however, that prior Amarin management did not hold the interests of shareholders as one of their top priorities...That is why I voted with Denner in the proxy battle and I will vote with him again if he can achieve a BO of $4 billion or more.
CBB...QUOTE..."Amazing how much government money went into Covid vaccinations. Pfizer certainly cleaned up...Big Time!"
Pfizer certainly took a huge risk when they paid Biontech $2 Billion up front for Biontech's Covid Vaccine in the early stages of development...When the vaccine, which Pfizer later named Commiraty, proved successful in combating Covid, Pfizer deserved to be well compensated for taking that risk.
Now PFE is taking a much larger $43 billion risk by buying Seagan for ownership of their cancer drugs.
Innovation is about taking risks and being rewarded when the projects are successful...
Now, I hope PFE will take an exceedingly smaller risk by buying Amarin, with their already developed and proven effective drug, Vascepa, and then develop it into the global blockbuster it needs to be!
Nsleven...Thank you for posting this interesting case with Denner as a defendant...It is undeniable that strange things were happening in that case.
In the Amarin vs. Healthnet case, the outcome of which was of vital importance to Amarin, and which case has been settled... the terms of the settlement were suspiciously never disclosed to the shareholders by either PWO or by Denner...supposedly the reason for that failure was that the settlement terms forbade disclosure ...Whatever the reason, this is IMO unacceptable in a company owned by the public.
CBB...QUOTE..."Funny that BP has billions in cash available for acquisitions
and yet there is a government entity that can quash any deal they do not
want to go forward."
What is also funny is that as the courts are making it more difficult for small undercapitalized companies to innovate new drugs and recoup their expenses through patent exclusivity, government is making it difficult for BP to merge with smaller companies to defray the expenses inherent in innovating new drugs.
Government seems more interested in cheaper drugs for today than better drugs for tomorrow....Politicians seem to want to have it both ways..but...YOU CAN'T HAVE IT BOTH WAYS!
There is a break up fee of over $2 billion that PFE is contracted to pay Seagan if the FTC nixes their deal to acquire Seagan...as is becoming more likely....QUOTE..."Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal"
PFE could have easily bought Amarin for about $4 billion and owned Vascepa, a drug that has the potential to save more lives than all of Seagan's drugs.
Mar 14, 2023 — Pfizer has $43 billion riding on the acquisition...with a $2.224 billion “termination fee” it will have to pay Seagen should the PFE acquisition deal go sour.
Teva made the claim that a GSX win at the S.C. would bring on a rash of 'skinny label' law suits
The recent interpretation of the HW law by many courts is now the source of more law suits aimed at invalidating patents, with the purpose of paving the way for generic litigators to profit from 'skinny labels'...than it is the source of law suits over patent infringements due to the 'skinny labels', which resulted from those patent invalidations.
Do Teva's claim is false on its face.
Rose....Yes ! The generic companies are guilty of infringement...The usage figures are available to the generic company and they prove that the generic company has the intent to continue infringing.
Proving skinny label infringement can take two paths...
1. Infringement can be proven by an infringing label on the generic product...or by announcements by the generic company as to their product's uses for a patented indication.
2. Infringement can proven by very convincing data on how the product is being used for a patented indication.
In the case of Vascepa, an overwhelming number of prescriptions for generic Vascepa are being used for the patented CVD indication (97%) rather than for the unpatented high triglycerides indication (3%)
IMHO This was NOT the intention of the HW law as agreed on by the conservative Hatch and the liberal Waxman.
The liberals on the S.C. also saw how the HW law was being used by generic cos. unjustly to enrich themselves and, in the process, to thwart innovations.
Nsleven...Would you agree that the timing and the volumes for the sales and purchases for both Sarrissa and Morgan Stanley are too fortuitous to be a pure coincidence, instead of being related?
Nsleven...Denner, by Q4 2022,was anticipating a proxy battle with PWO.... He sold approx. 19 million of his 24 million Amarin shares, which he then already held, to Morgan Stanley in order to gain an ally, who would have a similar interest, as he did, to support his fight to make necessary changes to Amarin management... Denner's intention was...to buy these shares back over the next several months, as he eventually did....SMART MOVE!
Also, I find in interesting that MS continued to increase their Amarin share count after Denner won the proxy fight!
That is why V should be renamed EPA PURE.
Capt…PWO is gone…AB might now be more interested in hiring you.
I asked my cardiologist to do an epa level…He said my hospital doesn’t do that test….He does give me an Rx for V…V should be renamed EPA… or EPA PURE…
The MO canard really hurt Vascepa in the U.S. and Mitigate has a chance to put that to rest for good...Europe is in bad economic shape and is not the answer during the near and medium term...Amarin now needs to turn its attention back to the U.S. and explore whether there is any means available to improve sales and revenues here...AB is more ready to do this job than KM would have been and IMO that is why he was appointed CEO.
Lovaza has been proven to be ineffective in reducing CVD and, in spite of this, it was marketed into becoming a blockbuster...Amarin has been proven effective in reducing CVD and can have the same success.
KM previously said that a FDC was on the table...AB said that an AG was on the table and that we should hear about China by mid 2023...
We are still waiting to hear about MND2119...There is a saying that silence is 'golden'...but it has not proven to be 'golden' for Amarin.
Amarin seems to have given Eddingpharm near complete control of Vascepa in China...
QUOTE..."Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product."
" Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms."
What is left to be discovered is whether this deal between Amarin and Mochida allows Eddingpharm, as Amarin's licensee, to market MND-2119 in China...This is a product, which which Mochida is already pursuing in China with Sumimoto corp. as a partner.
PWO has never explained why he didn't support Marjac and EPADI in their appeal case base on the fraud that Hikma had used to win their decision at the ninth circuit.
Supporting that case would have been at little or no cost to Amarin ...PWO placed his desire to avoid embarrassing Kennedy and Covington ahead of the interests of Amarin's shareholders...after these attorneys exhibited legal malpractice in not detecting the fraud and calling the court's attention to the fraud.
Judge Du, who was uniformed of the fraud during the case, cited the fraudulently cropped document from the Mori study in her decision to invalidate Amarin's high trig patent for Vascepa...thus opening the way for generics to continuously infringe on Amarin's patent for patent to treat CVDs...as they do to this day.
Tal...I have been thinking along the same lines...
QUOTE..."Vascepa has no market value on its own. Its sole value resides rather in a reformulation of the molecule so that what gets sold is a new improved “Statin+” rather than Vascepa, thereby short-cutting the entire lengthy marketing regulatory approval / reimbursement / budget allocation / sales processes worldwide – processes that can be hindered by a variety of geopolitical, financial, economic, generic competition and bureaucratic factors.
Only a BP selling a statin can integrate this molecule into its product and ESTABLISHED market."
Thus far, Amarin has not taken advantage of its EXCLUSIVE CONTRACT with Mochida to 'collaborate' on new and improved molecules of EPA which Amarin can market in 'certain territories'...
Amarin paid Mochida $2 million up front at the signing of their agreement to 'collaborate' on new EPA products...It seems that this is the moment to bring this critical agreement out of Amarin's back room, dust it off, and put it to work.
IMO AB's next goal should be to explore finding a way to sell more EPA in the U.S.
KM did some good things in the time he was CEO of Amarin, but he also made some missteps during his short tenure in that role.
-KM judged wrong on educating Docs about Vascepa through computer messaging alone....which did not yield results.
-KM judged wrong when hired a fleet of reps in Germany prior to getting payment approvals from the government... and then had to fire them at significant expense to Amarin.
-KM judged wrong when he threw in his lot with PWO, who had previously demonstrated that he cared little about Amarin.
-KM judged wrong when he quit as CEO when he could have continued to be helpful to Amarin due his knowledge of Europe....Even if Amarin's was to be sold sold to a BP, he could have played a major role, leading its European subdivision.
On 5/6/23, I posed some questions on IHUB POST #408313...about the Amarin-Mochida deal of 2018...I understand that some of these questions would be difficult or impossible to answer at this time, but it would be appreciated if Amarin could issue a PR answering questions 6 and 7....Thank you.
Jas...QUOTE...Vascepa is actually cost-effective. If every patient that qualifies for Vascepa starts using it, it will save millions of lives and save the healthcare system millions of dollars. What’s the problem??"
IMO insurance companies don't much care about drugs that help their patients in the future ,i.e. after taking these drugs for a period of three to five years...because many of these same patients will have switched their policies to other insurers during that time...and these other NEW insurance companies will accrue the benefits of less cash outlay for less future hospitalizations for these patients that the OLD insurance companies will have subsidized out of their current cash .
Insurance companies advertise that their main interest is in the health of their patients...but their actual main interest is in their bottom line.
We can expect the patients and their families and their Docs to care , but it is naive to expect insurance companies to care.
Denner's strategy historically has been to buy undervalued companies, get their prices UP, and then sell those companies for a profit...NOT to short the stocks of his recently purchased companies DOWN and then to buy the stocks back at lower prices!...Denner's buy at lower prices-sell at higher prices strategy has worked pretty well for him thus far....He is not a trader looking to make pennies...He is an investor, looking to make dollars.
Rose..At the time that the FDA Adcom voted fifteen to zero in favor of Vascepa approval, it seemed to many here that Amarin was sitting on gold with Vascepa and J.T. seemed to agree with his confidence...He would have only have sold Amarin for diamonds...Right now, its selling for coppers.
Some important questions about China and the Amarin-Mochida agreement that we still awaiting information on..
1. What more is required of Vascepa to attain approval in China?
2. What can Amarin expect for reimbursement of Vascepa in China?
3. Will Mochida release their own version of EPA(Epadel) in competition with Amarin's Vascepa in China?
4. When MND-2119 is approved in China, will Amarin be able to market it there in competition with Mochida?
5. Will Mochida be able to market MND-2119 in the U.S.?
6. Are there royalties due to Mochida for the marketing of MND-2119 in the U.S or elsewhere?.
7. How does a change of ownership impact the Amarin-Mochida deal, if at all?
A.....QUOTE.." Are the silver bullets Sarissa, China, and MND-2119?
Good question...But, as of now now, we have been given only scraps of information about China and MND-2119.